Silence Therapeutics Accelerates Divesiran Trial Timeline Amid Financial Challenges
Event summary
- Phase 2 SANRECO trial of divesiran for PV now expected to report topline results in Q3 2026, accelerated from H2 2026.
- AstraZeneca will not advance SLN312 beyond Phase 1; Silence Therapeutics regains exclusive rights.
- Full-year 2025 revenue dropped to $0.6M from $43.3M in 2024 due to concluded collaborations.
- Net loss widened to $88.6M in 2025 from $45.3M in 2024, with R&D expenses stable at ~$67.8M.
The big picture
Silence Therapeutics' focus on clinical execution is evident in the expedited SANRECO trial, but financial pressures mount as collaboration revenue plummets. The company's ability to navigate these challenges will hinge on its pipeline strategy and potential new partnerships. In an industry where siRNA therapies are gaining traction, Silence must balance aggressive timelines with sustainable financial management.
What we're watching
- Clinical Execution
- How the accelerated SANRECO trial timeline will impact divesiran's regulatory pathway and commercial potential.
- Pipeline Strategy
- Whether Silence Therapeutics can effectively repurpose SLN312 after AstraZeneca's withdrawal from further development.
- Financial Sustainability
- The pace at which Silence Therapeutics can secure new partnerships or funding to offset declining collaboration revenue.
Our editorial coverage:
Related topics